February 22, 2022
Mr Beh Kian Teik is the Chief Executive Officer of the National Research Foundation (NRF). He is responsible for planning, reviewing, developing and implementing the national Research, Innovation and Enterprise (RIE) strategies and governance frameworks, to grow and sustain a vibrant RIE ecosystem in Singapore. He plays an instrumental role in obtaining national consensus on research priorities, to guide long-term strategic Research & Development (R&D) investment decisions by the NRF Board.
Kian Teik is concurrently the Executive Vice President of the Singapore Economic Development Board (EDB). He oversees EDB New Ventures. He works with corporate entrepreneurs with the passion and drive to create early stage ventures in Singapore. He has over twenty years’ experience of promoting Foreign Direct Investment (FDI) and building industries in the manufacturing and internationally tradeable services sectors.
Previously, he was responsible for EDB’s activities in innovation & industry incubation and led effort to foster industry-science linkages. In 2010, he was also the founding director of the Singapore Biomedical Sciences Industry Partnership Office, a unique inter-agency government organisation. In this role, he worked with senior Singapore scientists to partner industry to translate science to medicine, and with industry partners that desire to undertake R&D projects requiring the capabilities of multiple Singapore agencies, in basic sciences and clinical research.
Kian Teik joined EDB in February 1998 and has held roles of increasing responsibilities in EDB. His previous leadership roles included developing the biomedical sciences cluster, attracting European FDI from Europe and running the IT, planning, research and statistics operations. He is a Sundstrand-EDB and Glaxo-EDB scholar who graduated from the University of California, Berkeley with an MSc in Electrical Engineering, as well as a BSc in Electrical & Computer Engineering from the University of Illinois at Urbana-Champaign.
SINGAPORE, 7 July 2022 – MiRXES Pte Ltd, a Singapore-headquartered biotechnology company, whose mission is to save and improve lives through early, actionable, and personalized diagnoses with its innovative RNA-powered cancer early detection solutions, announced today the signing of a Memorandum of Understanding (MOU) that launched Project CADENCE (CAncer Detected Early caN be CurEd). Project CADENCE is the world’s first large-scale clinical research project for the discovery and validation of novel combinations blood-borne circulating microRNA (miRNA) and DNA methylation biomarkers that will lead to the development of a multi-cancer early detection test for up to nine high incidence and high mortality cancers, including lung, breast, colorectal, liver, stomach (gastric), esophageal, ovarian, pancreatic, and prostate cancers.
A new national consortium – the Consortium for Clinical Research and Innovation, Singapore (CRIS) – has been officially launched by the Minister for Health Mr Ong Ye Kung on 6 April 2022 CRIS brings together five key national R&D, clinical translation and service initiatives that will advance clinical research and innovation for Singapore, and establish important capabilities for a future-ready healthcare system